20
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

A Web-Based Survey of Patients Dispensed Viagra Connect® Behind the Counter in UK: An Evaluation of Effectiveness of Additional Risk Minimization Measures

ORCID Icon, , , , & ORCID Icon
Pages 1345-1358 | Received 06 Nov 2023, Accepted 29 May 2024, Published online: 26 Jun 2024

References

  • Yafi FA, Jenkins L, Albersen M, et al. Erectile dysfunction. Nat Rev Dis Primers. 2016;2(1):1–20. doi:10.1038/nrdp.2016.3
  • Goldstein I, Goren A, Li VW, Tang WY, Hassan TA. Epidemiology update of erectile dysfunction in eight countries with high burden. Sexual Med Rev. 2020;8(1):48–58. doi:10.1016/j.sxmr.2019.06.008
  • Shamloul R, Ghanem H. Erectile dysfunction. Lancet. 2013;381(9861):153–165. doi:10.1016/S0140-6736(12)60520-0
  • Bjerkeli PJ, Mulinari S, Zettermark S, Merlo J. Sociodemographic patterns in pharmacy dispensing of medications for erectile dysfunction in Sweden. Eur J Clin Pharmacol. 2018;74(2):209–218. doi:10.1007/s00228-017-2361-9
  • Miner MM, Kuritzky L. Erectile dysfunction: a sentinel marker for cardiovascular disease in primary care. Cleveland Clinic J Med. 2007;74(Suppl_3):S30–S37. doi:10.3949/ccjm.74.Suppl_3.S30
  • DeLay KJ, Haney N, Hellstrom WJ. Modifying risk factors in the management of erectile dysfunction: a review. World J Mens Health. 2016;34(2):89–100. doi:10.5534/wjmh.2016.34.2.89
  • Paulsen LH, Sørensen Bakke L, Jarbøl DE, Balasubramaniam K, Hansen DG. Associations between lifestyle, erectile dysfunction and healthcare seeking: a population-based study. Scandinavian J Prim Health Care. 2020;38(2):176–183. doi:10.1080/02813432.2020.1753347
  • Li JZ, Maguire TA, Zou KH, Lee LJ, Donde SS, Taylor DG. Prevalence, comorbidities, and risk factors of erectile dysfunction: results from a prospective real-world study in the United Kingdom. Int J Clin Pract. 2022;2022:1–10.
  • Burri A, Porst H. Results from an online survey investigating ED patients’ insights and treatment expectations. Int J Impot Res. 2015;27(5):191–196. doi:10.1038/ijir.2015.14
  • Salonia A, Bettocchi C, Carvalho J, et al. EAU guidelines on sexual and reproductive health. Eur Assoc Urol Guidelines. 2020;80(3):333–357. doi:10.1016/j.eururo.2021.06.007
  • Wang J, Re J, Wang Z. Mode of action of sildenafil. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1999;21(6):493–496.
  • Padma-Nathan H. Sildenafil citrate (Viagra) treatment for erectile dysfunction: an updated profile of response and effectiveness. Int J Impot Res. 2006;18(5):423–431. doi:10.1038/sj.ijir.3901492
  • Medicines & Healthcare Products Regulatory Agency M. Public assessment report – prescription only medicine to pharmacy medicine reclassification: Viagra Connect® 50mg film-coated tablets, Sildenafil Citrate (PL 00165/0392 – 0001, 2017). Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/662968/Viagra_Connect_POM_to_P_PAR_FINAL.pdf. Accessed May 4, 2022.
  • Lee LJ, Maguire TA, Maculaitis MC, et al. Increasing access to erectile dysfunction treatment via pharmacies to improve healthcare provider visits and quality of life: results from a prospective real-world observational study in the United Kingdom. Int J Clin Pract. 2021;75(4):e13849. doi:10.1111/ijcp.13849
  • Lem J, Collins J, Maguire T, Sobel RE. A web-based survey of UK pharmacists to assess the effectiveness of Viagra Connect® additional risk minimisation measures. Int J Clin Pharm. 2022;44(3):608–618. doi:10.1007/s11096-021-01339-7
  • Li JZ, Younus M, Taylor D, Donde S, Collins J, Zou KH Scottsdale, Arizona, US. January 9-11, 2023, International Conference on Health Policy Statistics (ICHPS). Real-world evidence for regulatory purposes: a survey of patients to evaluate the effectiveness of the Viagra Connect National Additional Risk Minimization Measure in the United Kingdom. Available from: https://ww3.aievolution.com/AMSTATevents/index.cfm?do=ev.viewEv&ev=1567.
  • Donde S, Younus M, Li J, et al. A Web-Based Survey of Patients Dispensed Viagra Connect Behind the Counter in the UK: An Evaluation of the Effectiveness of Additional Risk Minimization Measures. 111 River ST, Hoboken 07030-5774, NJ USA: Wiley; 2022:420–421.